The 2020 American Society of Hematology (ASH) Annual Meeting and Exposition was held virtually December 5 to 8. The meeting featured new research around the treatment of blood-related diseases, including cancers of the blood and bone marrow, such as leukemia and lymphoma.
In this podcast, Michael Williams, MD, ScM, discusses advances in treating leukemia and lymphoma in 2020 and research presented at the meeting.
- 3 new drugs approved in the last half of 2020 by the U.S. Food and Drug Administration (FDA) for the treatment of follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma [2:38].
- Results from the CAPTIVATE phase II clinical trial, which studied the outcome of combining 2 targeted therapy drugs, ibrutinib (Imbruvica) and venetoclax (Venclexta), for the treatment of chronic lymphocytic leukemia (CLL) [3:49].
- An update from a study evaluating the combination of ibrutinib with another targeted therapy drug, rituximab (Rituxan), in treating Waldenstrom macroglobulinemia, a type of non-Hodgkin lymphoma [6:22].
- Discussion of a report on chimeric antigen receptor (CAR) T-cell therapy, a type of immunotherapy, for the treatment of follicular lymphoma and marginal zone lymphoma [8:00].
Dr. Williams is the Byrd S. Leavell Professor of Medicine and Professor of Pathology at the University of Virginia School of Medicine. He serves as the chief of the Hematology/Oncology Division, physician lead for the Cancer Service Line, and associate director for Clinical Affairs in the UVA Cancer Center. Dr. Williams is the Cancer.Net Associate Editor for Lymphoma. View Dr. Williams’ disclosures.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page>.
Cancer.Net podcasts are edited for length and content.